Scholarlink

Introduction and Hypothesis <p>Female genital mutilation (FGM) is associated with female sexual dysfunction (FSD) through anatomical disruption and impaired genital vascular function. Phosphodiesterase-5 inhibition may enhance genital perfusion via nitric oxide–mediated pathways. We hypothesized that tadalafil improves sexual function and clitoral vascular parameters in women with FGM-related FSD.</p> Methods <p>In this randomized, single-blind, placebo-controlled trial, 66 women with FGM-related FSD were randomized; 52 completed follow-up and were included in a modified intention-to-treat analysis (tadalafil 5&#xa0;mg once daily, <i>n</i> = 25; placebo, <i>n</i> = 27) for 8&#xa0;weeks. Sexual function was assessed using the Female Sexual Function Index (FSFI). Their FGM type was classified on the basis of WHO criteria. Clitoral color Doppler ultrasonography measured peak systolic velocity (PSV), resistance index (RI), and pulsatility index (PI). The primary endpoint was the between-group difference in change in total FSFI score from baseline to 8&#xa0;weeks.</p> Results <p>Baseline characteristics were comparable between groups. Tadalafil significantly improved total FSFI score compared with placebo (mean change +5.47 vs −0.41; <i>p</i> &lt; 0.001). Improvements were observed across all FSFI domains except lubrication. Significant increases in clitoral PSV, RI, and PI were detected in the tadalafil group, whereas no significant changes occurred in the placebo group. Greater benefit was observed in women with type I FGM.</p> Conclusions <p>Once-daily tadalafil 5&#xa0;mg for 8&#xa0;weeks significantly improves sexual function and genital vascular parameters in women with FGM-related FSD, supporting its potential therapeutic role in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can Low Dose Tadalafil Improve the Sexual Functions in Women with Genital Mutilation?

  • 期刊论文

  • 发表日期：

    2026年4月20日

查看全文
  • Ahmed M. Rammah,
  • Samer Morsy,
  • Hussein Ali Hussein,
  • Sara M. Hassan,
  • Dalia Farouk,
  • Karem M. Daw

摘要

Introduction and Hypothesis

Female genital mutilation (FGM) is associated with female sexual dysfunction (FSD) through anatomical disruption and impaired genital vascular function. Phosphodiesterase-5 inhibition may enhance genital perfusion via nitric oxide–mediated pathways. We hypothesized that tadalafil improves sexual function and clitoral vascular parameters in women with FGM-related FSD.

Methods

In this randomized, single-blind, placebo-controlled trial, 66 women with FGM-related FSD were randomized; 52 completed follow-up and were included in a modified intention-to-treat analysis (tadalafil 5 mg once daily, n = 25; placebo, n = 27) for 8 weeks. Sexual function was assessed using the Female Sexual Function Index (FSFI). Their FGM type was classified on the basis of WHO criteria. Clitoral color Doppler ultrasonography measured peak systolic velocity (PSV), resistance index (RI), and pulsatility index (PI). The primary endpoint was the between-group difference in change in total FSFI score from baseline to 8 weeks.

Results

Baseline characteristics were comparable between groups. Tadalafil significantly improved total FSFI score compared with placebo (mean change +5.47 vs −0.41; p < 0.001). Improvements were observed across all FSFI domains except lubrication. Significant increases in clitoral PSV, RI, and PI were detected in the tadalafil group, whereas no significant changes occurred in the placebo group. Greater benefit was observed in women with type I FGM.

Conclusions

Once-daily tadalafil 5 mg for 8 weeks significantly improves sexual function and genital vascular parameters in women with FGM-related FSD, supporting its potential therapeutic role in this population.